JP2008520586A5 - - Google Patents

Download PDF

Info

Publication number
JP2008520586A5
JP2008520586A5 JP2007541495A JP2007541495A JP2008520586A5 JP 2008520586 A5 JP2008520586 A5 JP 2008520586A5 JP 2007541495 A JP2007541495 A JP 2007541495A JP 2007541495 A JP2007541495 A JP 2007541495A JP 2008520586 A5 JP2008520586 A5 JP 2008520586A5
Authority
JP
Japan
Prior art keywords
antibody
variable region
library
region
hybrid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007541495A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008520586A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/041825 external-priority patent/WO2006055778A2/en
Publication of JP2008520586A publication Critical patent/JP2008520586A/ja
Publication of JP2008520586A5 publication Critical patent/JP2008520586A5/ja
Pending legal-status Critical Current

Links

JP2007541495A 2004-11-16 2005-11-16 免疫グロブリン可変領域カセット交換 Pending JP2008520586A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62858104P 2004-11-16 2004-11-16
PCT/US2005/041825 WO2006055778A2 (en) 2004-11-16 2005-11-16 Immunoglobulin variable region cassette exchange

Publications (2)

Publication Number Publication Date
JP2008520586A JP2008520586A (ja) 2008-06-19
JP2008520586A5 true JP2008520586A5 (https=) 2009-01-08

Family

ID=36407771

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007541495A Pending JP2008520586A (ja) 2004-11-16 2005-11-16 免疫グロブリン可変領域カセット交換

Country Status (10)

Country Link
US (2) US20060134098A1 (https=)
EP (3) EP2343380B1 (https=)
JP (1) JP2008520586A (https=)
AU (1) AU2005306502B2 (https=)
CA (1) CA2587158C (https=)
DK (2) DK2343380T3 (https=)
ES (3) ES2881353T3 (https=)
PL (2) PL3540062T3 (https=)
PT (2) PT2343380T (https=)
WO (1) WO2006055778A2 (https=)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
BRPI0506629A (pt) * 2004-02-10 2007-05-02 Univ Colorado inibição do fator b, a via alternativa do sistema complemento e métodos relacionados
PT2343380T (pt) 2004-11-16 2019-09-18 Humanigen Inc Permuta de cassetes da região variável de imunoglobulina
WO2006128006A1 (en) * 2005-05-26 2006-11-30 The Regents Of The University Of Colorado Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
WO2008042024A2 (en) 2006-06-01 2008-04-10 Elan Pharmaceuticals, Inc. Neuroactive fragments of app
WO2008063898A2 (en) * 2006-11-08 2008-05-29 Kalobios Pharmaceuticals, Inc. Methods of treating idiopathic thrombocytopenia purpura using a gm-csf antagonist
EP2101780B1 (en) 2006-11-21 2013-10-09 Kalobios Pharmaceuticals, Inc. Methods of treating chronic inflammatory diseases using a gm-csf antagonist
US8398972B2 (en) * 2006-11-21 2013-03-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a GM-CSF antagonist
US20090075378A1 (en) * 2007-02-20 2009-03-19 Anaptysbio, Inc. Somatic hypermutation systems
PL3199180T3 (pl) 2007-03-08 2022-08-08 Humanigen, Inc. Przeciwciała przeciwko epha3 do leczenia guzów litych
CN101668773B (zh) * 2007-03-14 2016-08-31 亚力史制药公司 人工程化抗b因子抗体
WO2009012401A1 (en) * 2007-07-17 2009-01-22 Irm Llc Antagonist antibodies of protease activated receptor-1 (par1)
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
BRPI0819598A2 (pt) 2007-11-30 2017-05-09 Kalobios Pharmaceuticals Inc anticorpos para o antígeno pcrv da pseudomonas aeruginosa
WO2009114815A1 (en) 2008-03-13 2009-09-17 Dyax Corp Libraries of genetic packages comprising novel hc cdr3 designs
JP5780951B2 (ja) 2008-04-24 2015-09-16 ダイアックス コーポレーション 新規のｈｃｃｄｒ１、ｃｄｒ２、およびｃｄｒ３設計、ならびに新規のｌｃｃｄｒ１、ｃｄｒ２、およびｃｄｒ３設計を含む、遺伝子パッケージのライブラリ
WO2009134805A2 (en) * 2008-04-28 2009-11-05 Kalobios Pharmaceuticals, Inc. Antibodies to granulocyte-macrophage colony-stimulating factor
CA2751433A1 (en) 2009-02-04 2010-08-12 Kalobios Pharmaceuticals, Inc. Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection
US9079942B2 (en) 2009-02-09 2015-07-14 Epitomics, Inc. CDR-anchored amplification method
WO2010093814A1 (en) 2009-02-11 2010-08-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a gm-csf antagonist
AU2010221159B2 (en) 2009-03-06 2015-11-26 Humanigen, Inc. Treatment of leukemias and chronic myeloproliferative diseases with antibodies to EphA3
CN102459591B (zh) * 2009-05-20 2015-05-13 诺维莫尼公司 合成性的多肽文库以及用于建立具有天然多样性的多肽变体的方法
WO2011003098A1 (en) 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
US8293483B2 (en) 2009-09-11 2012-10-23 Epitomics, Inc. Method for identifying lineage-related antibodies
CA2777068C (en) * 2009-10-14 2020-05-26 Humanigen, Inc. Antibodies to epha3
AR079336A1 (es) 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
SG181893A1 (en) * 2009-12-22 2012-08-30 Hoffmann La Roche Sequence dependent aggregation
AU2011217848B8 (en) 2010-02-18 2015-09-24 The Regents Of The University Of California Integrin aVB8 neutralizing antibody
EP2553150A4 (en) * 2010-04-02 2013-08-14 Kalobios Pharmaceuticals Inc GENERATION OF ANTIBODIES FOR CERTAIN EPITOPES
WO2012109530A1 (en) 2011-02-11 2012-08-16 Irm Llc Pcsk9 antagonists
ES2926988T3 (es) 2011-03-15 2022-10-31 X Body Inc Métodos de cribado de anticuerpos
WO2012168491A1 (en) 2011-06-10 2012-12-13 Novartis Ag Pharmaceutical formulations of pcsk9 antagonists
WO2012170607A2 (en) 2011-06-10 2012-12-13 Novartis Ag Use of pcsk9 antagonists
EP2764021A2 (en) * 2011-10-05 2014-08-13 Kalobios Pharmaceuticals, Inc. Generation of antibodies to an epitope of interest that contains a phosphomimetic amino acid
AU2012328819B2 (en) 2011-10-26 2017-08-03 Elanco Tiergesundheit Ag Monoclonal antibodies and methods of use
US9803005B2 (en) 2012-05-24 2017-10-31 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody
WO2014084859A1 (en) 2012-11-30 2014-06-05 Novartis Ag Molecules and methods for modulating tmem16a activities
AR096601A1 (es) 2013-06-21 2016-01-20 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
NZ720769A (en) 2013-12-09 2022-10-28 Allakos Inc Anti-siglec-8 antibodies and methods of use thereof
DK3110446T3 (da) 2014-02-28 2022-02-28 Allakos Inc Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme
DK3157951T3 (da) * 2014-06-17 2020-08-17 Academia Sinica Humaniserede anti-ige-antistoffer, der tværbinder cd23 på b-lymfocytter, men ikke sensibiliserer mastceller
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
US10774145B2 (en) 2015-06-17 2020-09-15 Allakos Inc. Methods and compositions for treating fibrotic diseases
JP6654779B2 (ja) * 2015-10-13 2020-02-26 株式会社バイオピーク ターゲットを認識するタンパク質の発現スクリーニング法
US10604577B2 (en) 2015-10-22 2020-03-31 Allakos Inc. Methods and compositions for treating systemic mastocytosis
RU2018124307A (ru) 2015-12-04 2020-01-14 Новартис Аг Антительно-цитокиновые привитые композиции и способы применения для иммунорегуляции
US11052111B2 (en) 2015-12-08 2021-07-06 Chimera Bioengineering, Inc. Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
US20190270821A1 (en) 2016-09-13 2019-09-05 Humanigen, Inc. Epha3 antibodies for the treatment of pulmonary fibrosis
US11078298B2 (en) 2016-10-28 2021-08-03 Banyan Biomarkers, Inc. Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) and related methods
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
EP3618868A4 (en) 2017-05-05 2021-02-24 Allakos Inc. METHODS AND COMPOSITIONS FOR TREATING ALLERGIC EYE DISEASES
MY206158A (en) 2017-05-24 2024-12-02 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
WO2018215938A1 (en) 2017-05-24 2018-11-29 Novartis Ag Antibody-cytokine engrafted proteins and methods of use
WO2018215937A1 (en) 2017-05-24 2018-11-29 Novartis Ag Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
US10927168B2 (en) 2017-10-02 2021-02-23 Humanicen, Inc. Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab
AU2018345751A1 (en) 2017-10-02 2020-05-07 Humanigen, Inc. Methods of treating immunotherapy-related toxicity using a GM-CSF antagonist
US10899831B2 (en) 2017-10-02 2021-01-26 Humanigen, Inc. Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
US11130805B2 (en) 2017-10-02 2021-09-28 Humanigen, Inc. Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist
CA3122773A1 (en) 2018-12-26 2020-07-02 Xilio Development, Inc. Anti-ctla4 antibodies and methods of use thereof
CA3209364A1 (en) 2021-03-01 2022-09-09 Jennifer O'neil Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
EP4301467A1 (en) 2021-03-01 2024-01-10 Xilio Development, Inc. Combination of ctla4 and pd1/pdl1 antibodies for treating cancer

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3742105A (en) 1970-05-05 1973-06-26 S Kuroda Method for producing a seamless tubing
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) * 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
EP0368684B2 (en) * 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6969586B1 (en) * 1989-05-16 2005-11-29 Scripps Research Institute Method for tapping the immunological repertoire
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
CA2082160C (en) 1991-03-06 2003-05-06 Mary M. Bendig Humanised and chimeric monoclonal antibodies
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ES2156149T3 (es) * 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
US6309636B1 (en) * 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
ES2176484T3 (es) * 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
DK1034298T3 (da) * 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
AU2001275267A1 (en) 2000-06-05 2001-12-17 Corixa Corporation Leader peptides for enhancing secretion of recombinant protein from a host cell
AU2001268545A1 (en) 2000-06-21 2002-01-08 Alexion Pharmaceuticals, Inc. Libraries displaying human antibody fragments with hybrid complementarity determining regions
MXPA05000511A (es) * 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
JP4213586B2 (ja) 2001-09-13 2009-01-21 株式会社抗体研究所 ラクダ抗体ライブラリーの作製方法
US20030219839A1 (en) * 2001-09-20 2003-11-27 Katherine Bowdish Anti-PDGF antibodies and methods for producing engineered antibodies
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
WO2003099999A2 (en) * 2002-05-20 2003-12-04 Abmaxis, Inc. Generation and selection of protein library in silico
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
US7541440B2 (en) * 2002-09-30 2009-06-02 Immunomedics, Inc. Chimeric, human and humanized anti-granulocyte antibodies and methods of use
WO2004072266A2 (en) * 2003-02-13 2004-08-26 Kalobios Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
EP1761561B1 (en) * 2004-01-20 2015-08-26 KaloBios Pharmaceuticals, Inc. Antibody specificity transfer using minimal essential binding determinants
US7811563B2 (en) 2004-10-25 2010-10-12 Northwestern University Anti-addl antibodies and uses thereof
PT2343380T (pt) 2004-11-16 2019-09-18 Humanigen Inc Permuta de cassetes da região variável de imunoglobulina
PE20090329A1 (es) * 2007-05-30 2009-03-27 Abbott Lab Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos

Similar Documents

Publication Publication Date Title
JP2008520586A5 (https=)
CA2587158A1 (en) Immunoglobulin variable region cassette exchange
JP2009153527A5 (https=)
JP2019526622A5 (https=)
JP2007533304A5 (https=)
Shi et al. De novo selection of high-affinity antibodies from synthetic fab libraries displayed on phage as pIX fusion proteins
Smith et al. Demystified… recombinant antibodies
WO2012163520A4 (en) Dual targeting
JP2010536384A5 (https=)
WO2005069970A3 (en) Antibody specificity transfer using minimal essential binding determinants
NZ601342A (en) Antibodies that bind il-4 and/or il-13 and their uses
JP2010513539A5 (https=)
JP2012176953A5 (https=)
JP2019535254A5 (ja) 抗ｐｄ−ｌ１抗体および変異型
JP2007535471A5 (https=)
JP2009539348A5 (https=)
WO2005016111A3 (en) Antibodies directed to parathyroid hormone (PTH) and uses thereof
JP2020533016A5 (https=)
US12344959B2 (en) Antibody libraries with maximized antibody developability characteristics
JP2016516400A5 (https=)
US20200308256A1 (en) Antibody phage display library
JP2021500916A5 (https=)
JP2018505681A5 (https=)
JP2007501011A5 (https=)
JP2005512962A5 (https=)